Objectives: To clarify the potential role of vitamin D supplementation on bone metabolism in congestive heart failure (CHF) patients with low vitamin D status and insufficient dietary calcium intake. Subjects/Methods: One hundred and two ambulatory male CHF patients were recruited, of whom the majority was treated with loop diuretics. Nine patients died during follow-up. Additional 14 participants dropped out prematurely because their health status worsened markedly. Five patients had to be excluded due to lack of compliance. A daily vitamin D3 supplement plus 500 mg calcium (CaD group) or a placebo plus 500 mg calcium (Ca group) was given for 9 months. Biochemical parameters of vitamin D and bone metabolism were analyzed at baseline and after 9 months. Results: Median 25-hydroxyvitamin D concentrations increased from 41.7 to 103.0 nmol/l (Po0.001) in the CaD group and remained constant in the Ca group, while median calcium intake increased above 1200 mg/day in both groups. The percentage of patients with elevated parathyroid hormone levels (460 pg/ml), as well as the serum concentration of undercarboxylated osteocalcin, an indicator of osteoporotic fracture risk and the bone resorption marker C-telopeptide fell significantly in both study groups (Po0.025-0.001). At the end of the study period, biomarkers of bone turnover did not differ between groups. Conclusions: A vitamin D3 supplement of 50 mg/day has no additional beneficial effects on markers of bone metabolism in CHF patients with low initial 25-hydroxyvitamin D concentrations if an adequate daily calcium intake is guaranteed.
Introduction
Combined calcium and vitamin D supplementation can improve bone metabolism and bone mineral density, and can lower osteoporotic fracture risk in adults with low vitamin D status and insufficient dietary calcium intake (Chapuy et al., 1992 (Chapuy et al., , 2002 Dawson-Hughes et al., 1997) . To prevent osteoporotic fractures, serum 25-hydroxyvitamin D (25(OH)D) concentrations above 75 nmol/l have recently been recommended for elderly men and women (DawsonHughes et al., 2005; Bischoff-Ferrari et al., 2006) . We and others have already demonstrated that patients with congestive heart failure (CHF) have mean serum 25(OH)D concentrations below 50 nmol/l, elevated parathyroid hormone (PTH) levels, and low serum concentrations of the vitamin D hormone calcitriol (Shane et al., 1997; Schleithoff et al., 2003) . The low vitamin D status of these patients is probably due to low ultraviolet B radiation (UVB) exposure, as indicated by restricted outdoor activities and limited mobility (Kriegsman et al., 1997; Albanese et al., 1999) . Serum 25(OH)D is an independent regulator of intestinal calcium absorption (Barger-Lux et al., 1995; Devine et al., 2002; Heaney et al., 2003a, b) . Levels below 50 nmol/l can be associated with low intestinal calcium absorption rates (Barger-Lux et al., 1995) and elevated serum PTH levels (Malabanan et al., 1998) , and might thus predispose to an increased risk for a negative calcium balance and bone loss. In line with this suggestion, CHF patients have elevated urinary concentrations of bone resorption markers (Christ et al., 1996; Shane et al., 1997) , low blood levels of bone formation markers (Nishio et al., 2003; Schleithoff et al., 2003) , low bone mineral densities (Muchmore et al., 1992; Lee et al., 1994; Van Cleemput et al., 1995; Thiebaud et al., 1996; Shane et al., 1997; Rodino and Shane, 1998) , and a high osteoporotic fracture risk (Shane et al., 1997) . It has recently been suggested that the low femoral bone mineral density in CHF patients is at least in part related to low serum 25(OH)D concentrations (Kenny et al., 2006) . Nevertheless, the contribution of low serum vitamin D metabolites (25(OH)D and/or calcitriol) to the disturbed bone metabolism is unclear at present. Since calcium supplementation alone is able to reduce markers of bone resorption in subjects with inadequate dietary calcium supply (Kamel et al., 1998) and can reduce osteoporotic fractures in those subjects with low calcium intake who are compliant (Prince et al., 2006) , the additional benefit of vitamin D on bone health needs to be clarified. Therefore, we performed a prospective, placebocontrolled randomized trial with 50 mg vitamin D per day. A calcium intake above the recommended intake of 1000-1200 mg/day (Standing committee on the scientific evaluation of dietary reference intakes, Food and Nutrition Board, Institute of Medicine, 1997) was guaranteed by daily supplementation of both, the serum and the placebo group with 500 mg elemental calcium.
Materials and methods

Patients
One hundred and two male CHF patients were recruited at the Heart and Diabetes Center Nordrhein-Westfalen, Germany, between March 2002 and April 2003. Patients were ambulatory and were routinely seen at least two times a year. Only symptomatic patients with New York Heart Association functional class XII, where ordinary physical activity already results in fatigue and dyspnea, were included. Exclusion criteria were female gender (to eliminate menopausal-related changes in bone metabolism), hypercalcemia, serum creatinine concentration 42 mg/dl, nephrolithiasis, sarcoidosis, biventricular pacemaker implantation, acute heart insufficiency and actual intake of vitamin D and calcium supplements. All patients gave written informed consent to the study procedures, which were approved by the Ethics Committee of the Medical Association Westfalen-Lippe, Germany.
Study design
Patients were randomized in a double-blind manner to receive a daily supplement of 50 mg cholecalciferol (Vigantol Oel, Merck, Darmstadt, Germany) or a placebo (Migliol-Oel, Merck, Darmstadt, Germany). Fifty-two patients were initially assigned to the intervention group (designated CaD group) and 50 patients to the control group (designated Ca group). In addition, both groups received a daily supplement of 500 mg of calcium as calcium carbonate. The treatment was conducted for a period of 9 months. Study end points were biochemical markers of bone formation (intact osteocalcin, intact OC; undercarboxylated osteocalcin, ucOC), bone resorption (carboxy-terminal crosslinked telopeptide of type I collagen, CTx), and hormones controlling bone remodelling (PTH; 25(OH)D and calcitriol). We documented patient compliance by controlling the study medication at each visit (bottle counts) and by the analysis of serum 25(OH)D concentrations. The study patients' medical history and medical treatment were assessed with the use of hospital documents. Moreover, the patients had to complete a validated food record (Zittermann et al., 2000) on the day before each visit, to estimate dietary vitamin D and calcium intake. Blood specimens were collected from the antecubital vein of the study subjects after a 12 h-overnight fast at baseline and after 9 months. After centrifugation at room temperature for 20 min (1500 g), aliquots of the serum samples were frozen consecutively and stored at À801C until analyzed.
Biochemical analyses
Serum 25(OH)D was analyzed using a 125 I-labelled radioimmunoassay test kit supplied by Diasorin (Stillwater, MN, USA). Serum calcitriol was analyzed after solid-phase extraction by an enzyme-linked immunosorbent assay (ELISA) test kit (Immundiagnostik, Bensheim, Germany). CTx and intact PTH were measured by means of ELISA using commercial test kits supplied by DRG Diagnostics, Marburg, Germany and Nordic Bioscience Diagnostics, Hamburg, Germany, respectively. The intra-assay coefficients of variation (CVs) of the vitamin D metabolites, intact PTH and CTx were all below 7%, and all interassay CVs were below 9%. Serum intact osteocalcin (intact OC) was measured by an ELISA test kit supplied by DRG Diagnostics (Marburg, Germany). The assay uses monoclonal antibodies directed against distinct epitopes of human OC. N-and C-terminal fragments do not interfere with this test at their maximum levels found in normal and pathological samples. The CV is 2.5% at a level of 11.5 ng/ml and the interassay CV is 9.2% at a level of 9.4 ng/ml. Serum ucOC, an indicator of osteoporotic fracture risk (Szulc et al., 1993) , was measured by a commercially available ELISA test kit supplied by Takara Shuzo (Kyoto, Japan). The kit utilizes mouse monoclonal anti-ucOC antibodies to detect ucOC. The kit specifically measures ucOC with 5% cross-reactivity with human bone OC (probably carboxylated type). The intra-assay CV is 4.6% at a level of 6.9 ng/ml and the interassay CV is 5.7% at a level of 6.5 ng/ml. Serum concentrations of calcium (Ca), phosphate and albumin were analyzed using flame atomic absorption spectrometry (Ca; AAS 3030, Perkin-Elmer, Ueberlingen, Germany) and colorimetric test kits (phosphate and albu-min; Wako Chemicals, Neuss, Germany and BioMerieux, Nuertingen, Germany), respectively. The CVs for these methods were below 2.5%.
Statistics
Statistical evaluations were performed with SPSS, version 11 (Chicago, IL, USA). Categorical variables were reported using number or percent of observations. For comparative evaluations of categorical variables, Fisher's exact test was used. Since most continuous variables were non-normally distributed, as tested by the Kolmogorov-Smirnov test, they were expressed as median with interquartile range (IQR). We used the Mann-Whitney U-test to compare the values of the study groups at baseline. Results after 9 months are presented as change from baseline. We compared changes from baseline between study groups using the Mann-Whitney U-test. Moreover, we evaluated time effects within each study group using the Wilcoxon test. We used Spearman's rank correlation coefficient r s to assess interrelationships. P-values o0.05 (two-tailed test) were considered statistically significant and P-values between 0.05 and 0.10 were considered borderline significant.
Results
Patients' characteristics are presented in Table 1 . Clinical parameters and medical treatment did not differ between groups. Results of the food records revealed a daily dietary vitamin D intake of 1.35 mg (IQR: 0.80-2.50 mg) in the CaD group and 1.20 mg (IQR: 0.60-2.20 mg) in the Ca group (P40.05). Median dietary calcium intake was 983 mg/day (IQR: 741-1275 mg/day) in the CaD group and 839 mg/day (IQR: 656-1158 mg/day) in the Ca group. Thus, the median daily habitual calcium intake and the additional calcium supplement led to a total daily calcium intake above the recommended daily intake value of 1000-1200 mg in both study groups.
Of the 81 loop diuretic users and 21 nonusers, 51.9 and 18.8%, respectively, had baseline serum PTH levels above the reference range of the assay (460 pg/ml). At baseline, median serum concentrations of PTH, CTx and ucOC were higher, whereas intact OC concentration tended to be lower in the loop diuretic users compared to the nonusers. In detail, median PTH was 43.1 and 32.7 pg/ml, respectively (P ¼ 0.015), median CTx was 0.41 and 0.35 ng/ml, respectively (P ¼ 0.011), median ucOC was 7.49 and 6.67 ng/ml (P ¼ 0.012), respectively, and median intact OC was 4.31 and 4.34 ng/ml, respectively (P ¼ 0.073).
Nine patients died during follow-up. Additional 14 participants dropped out of the study prematurely because their health status worsened markedly: In detail, one patient (from the Ca group) developed nephrolithiasis, cardiac transplantation was performed in four patients, in three patients a biventricular pacemaker had to be implanted, and six study subjects could not complete the study due to an excessive impairment in health status such as stroke, resuscitation and high hospitalization rate. During followup five subjects (four in the CaD group, one in the Ca group) had to be excluded due to lack of compliance such as forgetfulness and overburden in study participation. Drop out rate did not differ between study groups (P40.05). Finally, we could evaluate blood samples of 33 men of the CaD group and of 41 men of the Ca group. Initial 25(OH)D concentrations were below 50 nmol/l in both study groups (Figure 1 ). Vitamin D supplementation increased median 25(OH)D concentrations by 61.3 nmol/l (Po0.001), leading to a median serum 25(OH)D level of 103 nmol/l, while the median 25(OH)D concentration only tended to increase in the Ca group by 2.9 nmol/l (Po0.1). Calcitriol tended to rise in the CaD group (Po0.1) but not in the Ca group (P40.1; Table 2 ). At baseline, 20.0 and 32.5% of the patients in the CaD and Ca group, respectively, had serum PTH levels above 460 pg/ml. Median PTH concentrations tended to fall in the CaD group (Po0.1), but did not change in the Ca group Intact OC fell in the Ca group only (Po0.01; Table 2 ). Serum calcium and phosphate levels remained unchanged in both study groups (Table 2) . At the end of the study period, changes from baseline differed significantly between groups regarding serum concentrations of 25(OH)D and calcitriol, whereas there were no differences in changes from baseline regarding serum levels of PTH and the bone markers ucOC, intact OC and CTx (Figures 2 and 3 ; Table 2 ). The use of medications did not change significantly within the study groups during follow-up and were not significantly different between groups at the end of the study period (data not shown).
When all serum samples at baseline and at 9 months were considered for data analysis, levels of PTH were related to intact OC (r s ¼ þ 0.28; Po0.001), CTx (r s ¼ þ 0.20; Po0.001) and ucOC (r s ¼ þ 0.12; Po0.05). Moreover, concentrations of intact OC and CTx were significantly higher and ucOC concentrations tended to be higher when all serum samples with elevated PTH levels were compared with all serum samples of PTH concentrations within the reference range (Table 3) . Vitamin D supplementation and bone metabolism SS Schleithoff et al in subjects with negligible UVB exposure (Heaney et al., 2003a, b) . However, our results also indicate that in patients with initial serum 25(OH)D concentrations of 40 nmol/l, a daily supplement of 50 mg vitamin D3 and 500 mg calcium for 9 months is not superior to 500 mg calcium alone in reducing bone turnover markers, despite a rise in serum 25(OH)D levels above 75 nmol/l. In both study groups, median habitual calcium intake was below the recommended daily calcium intake of 1000-1200 mg/day for healthy adults (Standing committee on the scientific evaluation of dietary reference intakes, Food and Nutrition Board, Institute of Medicine, 1997) . Moreover, the prolonged use of loop diuretics may have increased urinary calcium excretion in our patients, and may have further increased the need of dietary calcium (Blansfield and Andrew, 2000) . Our baseline data of higher PTH levels and a higher bone turnover in loop diuretic users compared to nonusers confirm this assumption. Thus, the calcium supplement may have guaranteed an adequate daily calcium intake in both study groups, and may be responsible for the reduction in bone turnover in both study groups. Our finding of a reduction in markers of bone resorption in both study groups are in line with earlier studies demonstrating that calcium supplementation is able to reduce bone resorption markers in subjects with inadequate dietary calcium intake (Kamel et al., 1998) . Moreover, our data of a reduction in serum ucOC in both study groups is in line with previous results demonstrating that a calcium-containing supplement leads to a reduction in serum ucOC levels (Panis et al., 2006) , and that seasonal variations in serum 25(OH)D levels influence serum ucOC concentrations (Szulc et al., 1993) , probably by influencing the amount of absorbed calcium.
A vitamin D-induced rise in 25(OH)D levels of 35 nmol/l is able to decrease serum PTH levels and to increase bone mineral density at the femoral neck in patients with initial serum 25(OH)D levels below 50 nmol/l (Ooms et al., 1995) . However, earlier results have also demonstrated that a rise in serum 25(OH)D from 30 to 70 nmol/l had no beneficial effects on biomarkers of bone metabolism if subjects had a recommended daily calcium intake. In this case, the surplus of absorbed calcium was at least in part excreted in the urine (Zittermann et al., 1998) . Since both, an increase in oral calcium intake and higher serum 25(OH)D levels result in a rise of intestinal absorbed calcium, calcium and vitamin D can obviously replace each other relative to their effects on calcium supply and calcium-mediated bone turnover. It has recently been suggested that vitamin D sufficiency can ensure ideal serum PTH values even when the calcium intake level is less than 800 mg/day, while a calcium intake above 1200 mg/day is not sufficient to maintain ideal serum PTH, as long as vitamin D status is below 45 nmol/l (Steingrimsdottir et al., 2005) . However, according to a study of Devine et al. (2002) , an increase in serum 25(OH)D of 60 nmol/l (for example from 40 to 100 nmol/l as observed in the CaD group of our study) increases gut calcium absorption in subjects with a habitual daily calcium intake of 900 mg from 38.7 to 46.5% only. Consequently, calcium supplementation with 500 mg/day may be more effective than increasing serum 25(OH)D levels by 60 nmol/l to elevate the amount of intestinal absorbed calcium. Our study results support these theoretical considerations. Moreover, results are in line with earlier data demonstrating that an increase in dietary calcium intake of 750 mg/day is more effective than an increase in serum 25(OH)D levels of 60 nmol/l in improving bone metabolism and bone mineral density in subjects with habitual calcium intake of only 900 mg/day (Peacock et al., 2000) .
The significant reduction of PTH levels 460 pg/ml during follow-up in both, the Ca group and the CaD group may explain some beneficial effects on bone turnover markers. This assumption is supported by the relationship of PTH levels with different bone markers (see Results section and Table 3 ). However, there is also evidence that a change in serum PTH levels is not necessary to result in a decrease of bone turnover markers in subjects with improved calcium supply (Kenny et al., 2004) . These data are in line with our finding that bone turnover markers decreased in both study groups during follow-up, whereas median PTH levels remained unchanged.
From the scientific point of view it would have been interesting to have a third group of subjects without vitamin D and/or calcium supplementation included. However, dietary calcium intake in Western countries is often below the calcium recommendation of 1000-1200 mg/day (Ervin and Kennedy-Stephenson, 2002) . This was also the case in our study groups (see Results section). As inadequate calcium intake can adversely affect bone metabolism (see before), we believe that it would have been unethical not to supplement both study groups with calcium. Moreover, to our opinion only investigations in subjects with recommended calcium intake can clarify the potential additional benefit of vitamin D on bone health.
In summary, our data demonstrate that a rise in serum 25(OH)D levels from approximately 40-100 nmol/l has no additional beneficial effects on bone metabolism in CHF patients if an adequate daily calcium intake is guaranteed.
